15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Benitec Biopharma Ltd ADR, 5 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $20.00 to $32.00, a moderate spread. The average target of $25.60 sits 121% above the current $11.58. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 4 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.28 next quarter toward $-1.15 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy5100%
Hold00%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Benitec Biopharma Ltd ADR.
As of Jul, 5 of 5 firms rate BNTC a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BNTC EPS & revenue forecast
EPS · NEXT QUARTER
$-0.28
Range $-0.31 – $-0.25 · 3 analysts · +27% YoY
Next period, 3 analysts expect Benitec Biopharma Ltd ADR to earn $-0.28 a share (range $-0.31 – $-0.25), versus $-0.22 a year earlier. , growing to $-1.15 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0)., rising to $21.9M next year.
Top analysts covering Benitec Biopharma Ltd ADR
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BNTC.
#1
Silvan Tuerkcan
JMP Securities · Rank #29
Buy
$22.00+90.0% to target
Overall win rate
50%
+ Follow
#2
Yasmeen Rahimi
Piper Sandler · Rank #152
Buy
$30.00+159.1% to target
Overall win rate
34%
+ Follow
#3
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Buy
$32.00+176.3% to target
Overall win rate
37%
+ Follow
#4
Cory Kasimov
Evercore ISI Group
Buy
$25.00+115.9% to target
Coverage
—
+ Follow
#5
Andreas Argyrides
Oppenheimer
Buy
$29.00+150.4% to target
Coverage
—
+ Follow
BNTC stock forecast FAQ
What is BNTC's average 12-month price target?+
The 5 analysts with a live target average $25.60 for Benitec Biopharma Ltd ADR over the next 12 months, ranging from a $32.00 high to a $20.00 low.
Is BNTC stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 5 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for BNTC?+
The Street-high target is $32.00 (HC Wainwright & Co.), and the Street-low is $20.00 (JMP Securities). The average of all 5 active targets is $25.60.
How many Wall Street analysts cover BNTC?+
5 analysts have an active rating on Benitec Biopharma Ltd ADR, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering BNTC?+
Among analysts who currently cover BNTC, Silvan Tuerkcan of JMP Securities has the strongest overall Quantellect track record (Rank #29). Their current call is Buy with a $22.00 target.
What is Benitec Biopharma Ltd ADR's projected EPS for next quarter?+
The consensus estimate is $-0.28 per share (range $-0.31 – $-0.25) across 3 analysts, rising to $-1.15 the following year.
How much revenue is Benitec Biopharma Ltd ADR expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0), growing to $21.9M next year.
Have analysts been upgrading or downgrading BNTC lately?+
As of Jul, 5 of 5 firms rate BNTC a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BNTC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
